Hosted on MSN

Key DNA complex connected to polymerase inhibitor cancer-drug resistance discovered

Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have made one of the most important discoveries to date in the study and treatment of BRCA1-deficient ...
BioWorld

RMC-5127, a novel tri-complex inhibitor with efficacy in KRAS G12V-mutant tumor models

Researchers from Revolution Medicines Inc. presented the discovery and preclinical characterization of RMC-5127, a novel noncovalent, tri-complex inhibitor of GTPase KRAS (G12V mutant), or KRAS G12V ...
Seeking Alpha

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor ...

REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
Business Insider

Quanta Therapeutics Presents Preclinical Data Establishing that Direct Multi-KRAS Inhibitors Retain Strong Activity Against Resistance Mechanisms Acquired from Treatment with ...

– Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to daraxonrasibin KRAS-mutated colorectal cancer cells – – Data support ...
Business Wire

Ajax Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...